Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: Related to disease duration?

Clinical Rheumatology

Volumn 26, Issue 8, 2007, Pages 1248-1253

  Shinjo, Samuel K ^a   Maia Júnior, Otacílio O ^a   Tizziani, Vivian A P ^a   Morita, Celso ^a   Kochen, Jussara A L ^a   Takahashi, Walter Y ^a   Laurindo, Ieda M M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chloroquine diphosphate; Maculopathy; Rheumatoid arthritis; Risk factor

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; FLUORESCEIN; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BIOMICROSCOPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; MEDICAL RECORD; MYDRIASIS; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULOPATHY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SCREENING TEST; STATISTICAL SIGNIFICANCE; VISUAL DISORDER;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 34447121885     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0478-9     Document Type: Article

References (40)

1. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjögren's syndrome with hydroxychloroquine: A retrospective, open-label study. Lupus 5:S31-S36
2. Meinao IM, Sato EI, Andrade LEC, Ferraz MB, Atra E (1996) Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 5:237-241
3. Olson NY, Lindsley CB (1986) Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16:1545-1547
4. Ryes RI (1997) Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 36:799-805
5. Weinberg DV, D'Amico DJ (1994) Retinal toxicity of systemic drugs. In: Albert DM, Jakobiec FA (eds) Principles and practice of ophthalmology: clinical practice. Saunders, Philadelphia, pp 3284-3285
6. Cambiaggi A (1957) Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol 57:451-457
7. Bernstein H, Zvaifler N, Rubin M, Mansour AM (1963) The ocular deposition of chloroquine. Invest Ophthalmol 2:384-392
8. Easterbrook M (1987) Dose relationships in patients with early chloroquine retinopathy. J Rheumatol 14:472-475
9. Henkind P, Rothfield NF (1963) Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 269:433-439
10. Cox NH, Paterson WD (1994) Ocular toxicity of antimalarial in dermatology: A survey of current practice. Br J Dermatol 131:878-882
11. Finbloom DS, Silver K, Newsome DA, Gunkel R (1985) Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 12:692-694
12. Bernstein HN (1983) Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 75:25-34
13. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF; American Academy of Ophthalmology (2002) Recommendations of screening for chloroquine and hydroxychloroquine retinopathy. A Report by the American Academy of Ophthalmology. Ophthalmology 109:1377-1382
14. Arnett FX, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang SR, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DII, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
15. Easterbrook M (1992) Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 27:237-239
16. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychlroquine: A reappraisal. Ophthalmology 110:1321-1326
17. Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD (2001) Progression of hydroxychloroquine retinopathy after discontinuation of therapy: Case report. Chang Gung Med J 24:329-334
18. Sassani JW, Brucker AJ, Cobbs W, Campbell C (1983) Progressive chloroquine retinopathy. Ann Ophthalmol 15:19-22
19. Bernstein H, Zvaifler N, Rubin M, Mansour AM (1963) The ocular deposition of chloroquine. Invest Ophthalmol 2:384-392
20. Henkind P, Rothfield NF (1963) Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 269:433-439
21. Cursiefen C, Grunert U, Junemann A (1997) Chloroquine-induced bull′s eye maculopathy without electrophysiologic changes. Klin Monatsbl Augenheilkd 210:400-401
22. Inada ET, Watanabe KP, Tanaka SG, Sakakisbara LA (2005) Ocular toxicity caused by chloroquine: Case report. Arq Bras Oftalmol 68:407-409
23. Lai WW, Lam DS (2005) Chloroquine-induced bull's eye maculopathy. Hong Kong Med J 11:55-57
24. Rynes RI, Krohel G, Falbo A, Reineck RD, Wolfe B, Bartholomew LE (1979) Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum 22:833-836
25. Tobin D, Krohel G, Rynes RI (1982) Hydroxychloroquine, seven-year experience. Arch Ophthalmol 100:81-83
26. Araiza-Casillas R, Cárdenas F, Morales Y, Cardiel MH (2004) Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 13:119-124
27. Dubois EL (1978) Antimalarial in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 8:33-51
28. Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (2004) Kelly's textbook of rheumatology, 7th edn, vol I, Section VIII
29. Scherbel AL, Mackenzie, AH, Nousek JE, Atdjian M (1965) Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy. N Engl J Med 273:360-366
30. Elman A, Gullberg R, Nilsson E, Rendahl I, Wachtmeister L (1976) Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol 5:161-166
31. Marks JS (1982) Chloroquine retinopathy: Is there a safe daily dose? Ann Rheum Dis 41:52-58
32. Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75:40-45
33. Cruess AF, Schachat AP, Nicholl J, Augsburger JJ (1985) Chloroquine retinopathy. Is fluorescein angiography necessary? Ophthalmology 92:1127-1129
34. Easterbrook M (1998) Current concepts in monitoring patients on antimalarials (Editorial). Aust N Z J Ophthalmol 26:101-103
35. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K (1996) Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 55:187-189
36. Weise EE, Yannuzzi LA (1974) Ring maculopathies mimicking chloroquine retinopathy. Am J Ophthalmol 78:204-210
37. Sutter EE, Tran D (1992) The field topography of ERG components in man. I The photopic luminance response. Vision Res 32:433-436
38. Penrose PJ, Tzekov RT, Sutter EE, Fu AD, Allen AW Jr, Fung WE, Oxford KW (2003) Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina 23:503-512
39. Tzekov RT, Serrato A, Marmor MF (2004) ERG findings in patients using hydroxychloroquine. Doc Ophthalmol 108:87-97
40. Kellner U, Kraus H, Foerster MH (2000) The multifocal electroretinogram can detect retinal dysfunction in chloroquine retinopathy even when the full-field electroretinogram is normal and retinal alteration is subtle. Graefes Arch Clin Exp Ophthalmol 238:94-97